INCYINCYTE CORP
Services-Commercial Physical & Biological Research
- Revenue
- $5.1B
- 21% YoY
- Operating margin
- 29.5%
- 1936% YoY
- EBITDA
- $1.6B
- 968% YoY
- Market cap
- $24.6B
- Employees
- 2,844
- $2M revenue each
- Net debt / EBITDA
- 9.8×
- $15.8B net debt
- AI in 10-K
- 0.9
- mentions per 10K words
Takeover score 2 of 13
Fixable underperformance 1 of 7
- TSR below peersYes4 of 5 years3+ of last 5 years
- High CEO pay despite TSRNo—Median CEO pay ≥ $15M while TSR trails
- Earnings not backed by cashNo110% of net incomeCash flow under 80% of net income
- Dilutive SBCNo5% of revenueOver 10% of revenue
- Payouts exceed cash flowNo0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyNo2% of assetsOver 40% of assets
- Shareholder dissentNo84% lowest supportAny vote under 80% support
Buyer economics 0 of 4
- Low revenue per employeeNo$2M · 100th pctBottom quartile of its SIC industry
- Quiet on AINo0.9 per 10K words · 32nd pctBottom quartile of AI mentions in 10-Ks
- Net cashNo9.8× EBITDA net debtMore cash than debt, positive EBITDA
- Buyout-sizedNo$24.6B market capMarket cap $500M–$5B
Catalysts 1 of 2
- Active 13DNo0 filingsActive-intent 13D in 18 months
- Net insider sellingYes−$58M netNet sales over $10M in 12 months
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $3.0B | $3.4B | $3.7B | $4.2B | $5.1B | 21% |
| Operating income | $586M | $579M | $621M | $61M | $1.5B | 2369% |
| Net income | $949M | $341M | $598M | $33M | $1.3B | 3847% |
| Operating cash flow | $749M | $970M | $496M | $335M | $1.4B | 322% |
| Capex | $181M | $78M | — | — | — | |
| Stock-based comp | $183M | $188M | $216M | $266M | $249M | 6.3% |
| Buybacks | — | $0 | $0 | $2.0B | $0 | 100% |
Deal filings
None.
13D filers
| Filed | Filer | Form | Stake | Intent |
|---|---|---|---|---|
| May 11, 2026 | BAKER BROS. ADVISORS LP | SCHEDULE 13D/A | 15.4% | Passive |
| Feb 10, 2026 | BAKER BROS. ADVISORS LP | SCHEDULE 13D/A | 47.2% | Passive |
| Jun 14, 2024 | BAKER BROS. ADVISORS LP | SC 13D/A | 16.1% | Passive |
| May 13, 2024 | BAKER BROS. ADVISORS LP | SC 13D/A | 16.0% | Passive |
| May 9, 2024 | BAKER BROS. ADVISORS LP | SC 13D/A | 16.2% | Passive |
| Mar 15, 2023 | BAKER BROS. ADVISORS LP | SC 13D/A | 16.3% | Passive |
| Mar 10, 2022 | BAKER BROS. ADVISORS LP | SC 13D/A | 16.4% | Passive |
| Feb 14, 2022 | BAKER BROS. ADVISORS LP | SC 13D/A | 15.7% | Passive |
| May 18, 2021 | BAKER BROS. ADVISORS LP | SC 13D/A | 14.6% | Passive |
| Apr 29, 2020 | BAKER BROS. ADVISORS LP | SC 13D/A | 14.8% | Passive |
Insider trading
- Open-market buys, 12 mo
- $0 · 0
- Open-market sells, 12 mo
- $58M · 47
- Net
- −$58M
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | — | — | 114 | 120 |
| FY2024 | — | — | 79 | 91 |
| FY2023 | — | — | 72 | 92 |
| FY2022 | — | — | 92 | 89 |
| FY2021 | — | — | 84 | 99 |